TrialJournal of gynecologic oncology2022

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.

Junsik Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.